Get the Stockscreener App
13.40
0.87%
0.115
After Hours:
13.40
Surgery Partners Inc stock is traded at $13.40, with a volume of 967.71K.
It is up +0.87% in the last 24 hours and down -9.03% over the past month.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
See More
Previous Close:
$13.29
Open:
$13.27
24h Volume:
967.71K
Relative Volume:
0.61
Market Cap:
$1.75B
Revenue:
$3.34B
Net Income/Loss:
$97.10M
P/E Ratio:
-22.52
EPS:
-0.595
Net Cash Flow:
$208.00M
1W Performance:
-3.94%
1M Performance:
-9.03%
6M Performance:
-15.40%
1Y Performance:
-40.71%
1-Day Range:
$13.21
$13.50
1-Week Range:
$13.14
$14.20
52-Week Range:
$11.41
$24.10
Surgery Partners Inc Stock (SGRY) Company Profile
Name
Surgery Partners Inc
Sector
Industry
Phone
615-234-5900
Address
340 SEVEN SPRINGS WAY, BRENTWOOD, TN
Compare SGRY vs HCA, THC, DVA, FMS, EHC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGRY
Surgery Partners Inc
|
13.40 | 1.74B | 3.34B | 97.10M | 208.00M | -0.595 |
HCA
Hca Healthcare Inc
|
394.07 | 87.09B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
173.78 | 15.33B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
198.52 | 12.75B | 13.84B | 1.10B | 1.49B | 10.42 |
FMS
Fresenius Medical Care Ag Adr
|
21.64 | 12.09B | 22.18B | 1.36B | 2.00B | 1.9216 |
EHC
Encompass Health Corp
|
104.96 | 10.36B | 6.07B | 793.80M | 464.40M | 5.9914 |
Surgery Partners Inc Stock (SGRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Resumed | JP Morgan | Neutral |
| Jul-28-25 | Resumed | BofA Securities | Buy |
| Dec-16-24 | Initiated | BofA Securities | Buy |
| Oct-14-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-28-24 | Initiated | Macquarie | Outperform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Nov-14-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jun-02-23 | Upgrade | BofA Securities | Neutral → Buy |
| May-12-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-23-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Nov-30-21 | Initiated | Barclays | Overweight |
| Nov-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-01-21 | Initiated | JP Morgan | Neutral |
| Oct-18-21 | Initiated | SVB Leerink | Outperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Jun-23-21 | Resumed | Stifel | Hold |
| Sep-17-20 | Reiterated | The Benchmark Company | Buy |
| Apr-27-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-03-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-14-20 | Reiterated | The Benchmark Company | Buy |
| Nov-16-18 | Initiated | UBS | Neutral |
| Sep-18-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jun-28-18 | Upgrade | Stifel | Sell → Hold |
| Jan-30-18 | Reiterated | The Benchmark Company | Buy |
| Nov-01-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-09-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Aug-09-17 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Aug-09-17 | Downgrade | Stifel | Hold → Sell |
| Apr-24-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Stifel | Buy → Hold |
| Jan-31-17 | Initiated | The Benchmark Company | Buy |
| Jun-10-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Mar-14-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-27-15 | Initiated | Stifel | Buy |
| Oct-26-15 | Initiated | RBC Capital Mkts | Outperform |
| Oct-26-15 | Initiated | Raymond James | Strong Buy |
View All
Surgery Partners Inc Stock (SGRY) Latest News
A Look At Surgery Partners (SGRY) Valuation After A Difficult Year For Shareholders - Yahoo Finance
CORRECTED: Distalmotion Accelerates US Commercial Momentum in Ambulatory Surgery Centers - Yahoo Finance UK
Distalmotion Accelerates US Commercial Momentum in Ambulatory Surgery Centers - Yahoo Finance
Surgery Partners stock (US85701Q1031): Earnings date in focus ahead of August report - AD HOC NEWS
Deals tracker: Medtronic to acquire SPR Therapeutics for $650M - Modern Healthcare
Surgery Partners Inc stock (US85701Q1031): earnings momentum and M&A reshape outlook - AD HOC NEWS
[SCHEDULE 13G/A] Surgery Partners, Inc. Amended Passive Investment Disclosure - Stock Titan
Trading Systems Reacting to (SGRY) Volatility - Stock Traders Daily
5 Revealing Analyst Questions From Surgery Partners’s Q1 Earnings Call - Yahoo Finance
Jefferies Remains Bullish on Surgery Partners (SGRY) Post Q1 - Insider Monkey
Surgery Partners Delivered Solid Q1 Beat Amid Stabilizing Portfolio, RBC Says - Moomoo
BofA Securities Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $17.5 - Moomoo
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Ambulatory Surgical Centers Market to Reach US$ 162.13 Billion - openPR.com
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $16.25 to $21 - Moomoo
MSN Money - MSN
A Look At Surgery Partners (SGRY) Valuation After Reaffirmed Guidance And Positive First Quarter Results - Sahm
Is Surgery Partners’ (SGRY) Q1 Beat And Reaffirmed 2026 Outlook Altering The Investment Case? - Yahoo Finance
Stronger Q1 Results And Reaffirmed Outlook Might Change The Case For Investing In Surgery Partners (SGRY) - Sahm
Number of shareholders of Surgery Partners, Inc. – LSX:A14YWP - TradingView
Surgery Partners outlines 2026 revenue of $3.35B-$3.45B and adjusted EBITDA of at least $530M as portfolio optimization targets mid-2026 announcement - MSN
Surgery Partners SGRY Q1 2026 Earnings Transcript - AOL.com
Surgery Partners price target raised to $17 from $15 at Jefferies - TipRanks
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
FMR LLC holds 2.19M SGRY shares (1.7%) — Surgery Partners (NYSE: SGRY) - Stock Titan
Surgery Partners Q1 2026 Earnings Call Transcript - Sahm
Surgery Partners, Inc. (NASDAQ:SGRY) Q1 2026 Earnings Call Transcript - Insider Monkey
Surgery Partners Q1 2026 earnings preview - MSN
KeyBanc Maintains Surgery Partners(SGRY.US) With Hold Rating - Moomoo
Surgery Partners Q1 2026 slides: revenue beats amid regulatory pressures By Investing.com - Investing.com Australia
SGRY Q1 Deep Dive: Stable Margins and Physician Recruitment Offset Volume Headwinds - The Globe and Mail
Surgery Partners Balances Growth Ambitions With Rising Headwinds - TipRanks
Surgery Partners : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Surgery Partners Q1 Earnings Call Highlights - Yahoo Finance
Surgery Partners (SGRY) Q1 2026 revenue rises as net loss narrows - Stock Titan
Surgery Partners Releases Q1 2026 Financial Results - AlphaStreet
Surgery Partners | 8-K: SURGERY PARTNERS, INC. ANNOUNCES FIRST QUARTER 2026 RESULTS REAFFIRMS FULL YEAR 2026 GUIDANCE - Moomoo
Surgery Partners (SGRY) reports Q1 loss, tops revenue estimates - MSN
Surgery Partners Narrows Slips to a Loss in Q1 2026, Beats Estimates - AlphaStreet
Surgery Partners Q1 2026 slides: revenue beats amid regulatory pressures - Investing.com
Earnings call transcript: Surgery Partners Q1 2026 earnings beat forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Surgery Partners Q1 2026 earnings beat forecasts - Investing.com UK
Surgery Partners Q1 Swings to Adjusted Net Loss, Revenue Rises; Full-Year 2026 Revenue Guidance Reaffirmed - marketscreener.com
Surgery Partners reports Q1 adjusted EPS (3c), consensus (14c) - TipRanks
Surgery Partners Inc Stock (SGRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.74%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):